Shares of pharmaceutical giant Bristol-Myers Squibb (BMY -8.82%) have soared more than 40% since the start of 2013, and investor confidence in this high-flying stock is still high. However, in the world of health care investing, catalysts can either push shares up further or cool the market's optimism.
In the following video, a segment from the The Motley Fool's health care show Market Checkup, analysts Max Macaluso and David Williamson discuss three key catalysts that Bristol-Myers investors must watch. Among them are results from its oncology pipeline, the Food and Drug Administration decision on its type 2 diabetes drug Forxiga -- which it shares with AstraZeneca (AZN 5.48%) and could compete with Johnson & Johnson's (JNJ -1.09%) Invokana in the U.S. market -- and its virology program, which has lost ground to biotech Gilead Sciences (GILD -2.70%).
